Equillium, Inc.
NASDAQ:EQ
Overview | Financials
Company Name | Equillium, Inc. |
Symbol | EQ |
Currency | USD |
Price | 0.716 |
Market Cap | 25,382,625 |
Dividend Yield | 0% |
52-week-range | 0.56 - 3.25 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Bruce D. Steel C.F.A. |
Website | https://equilliumbio.com |
An error occurred while fetching data.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD